{"nctId":"NCT00195650","briefTitle":"Long Term Open Label Continuation Study","startDateStruct":{"date":"2000-07"},"conditions":["Rheumatoid Arthritis"],"count":846,"armGroups":[{"label":"Adalimumab","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab"]}],"interventions":[{"name":"Adalimumab","otherNames":["Humira, ABT-D2E7"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Participant was in a prior D2E7 (adalimumab) study\n* Participant was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.\n\nExclusion Criteria\n\n* Participant was considered by the investigator, for any reason, to be an unsuitable candidate for the study\n* Participant was a female subject who is pregnant or breast-feeding or considering becoming pregnant\n* Participant had any ongoing chronic or active infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520","description":"ACR20 response criteria were: \\>=20% improvement in tender joint count; \\>=20% improvement in swollen joint count; and \\>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260","description":"ACR20 response criteria were: \\>=20% improvement in tender joint count; \\>=20% improvement in swollen joint count; and \\>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"402","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 520","description":"ACR50 response criteria were: \\>=50% improvement in tender joint count; \\>=50% improvement in swollen joint count; and \\>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null}]}]}]},{"type":"SECONDARY","title":"Reported Adverse Events","description":"Adverse events were collected during the course of the study (after the first adalimumab injection in this continuation study DE020 through 70 days after the last adalimumab injection) for all participants who received at least 1 dose of open-label adalimumab in the continuation study (Full Analysis Set). The number of participants experiencing any adverse event (serious and non-serious) are summarized. See the Reported Adverse Events section for details.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"808","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260","description":"ACR50 response criteria were: \\>=50% improvement in tender joint count; \\>=50% improvement in swollen joint count; and \\>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"279","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 520","description":"ACR70 response criteria were: \\>=70% improvement in tender joint count; \\>=70% improvement in swollen joint count; and \\>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 260","description":"ACR70 response criteria were: \\>=70% improvement in tender joint count; \\>=70% improvement in swollen joint count; and \\>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 520","description":"Clinical remission on modified Disease Activity Score (DAS28) was a value \\<2.6; \\>=2.6 to \\<=3.2 indicated low disease activity; \\>3.2 to \\<=5.1 indicated moderate disease activity; and \\>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 260","description":"Clinical remission on modified Disease Activity Score (DAS28) was a value \\<2.6; \\>=2.6 to \\<=3.2 indicated low disease activity; \\>3.2 to \\<=5.1 indicated moderate disease activity; and \\>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520","description":"The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"0.662"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260","description":"The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.59","spread":"0.628"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":432,"n":846},"commonTop":["Upper respiratory tract infection","Rheumatoid arthritis","Sinusitis","Nasopharyngitis","Bronchitis"]}}}